Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2014, Article ID 541709, 7 pages
http://dx.doi.org/10.1155/2014/541709
Research Article

Assessment of Lipocalin 2, Clusterin, Soluble Tumor Necrosis Factor Receptor-1, Interleukin-6, Homocysteine, and Uric Acid Levels in Patients with Psoriasis

1Department of Dermatology, Konya Training and Research Hospital, Meram, 42023 Konya, Turkey
2Department of Microbiology, Faculty of Medicine, Afyon Kocatepe University, 03200 Afyon, Turkey
3Department of Dermatology, Faculty of Medicine, Sutcu Imam University, 46050 Kahramanmaras, Turkey

Received 31 January 2014; Accepted 12 March 2014; Published 2 April 2014

Academic Editor: Silvia Persichilli

Copyright © 2014 Arzu Ataseven et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. M. Ceyhan, M. Yildirim, B. M. Ceyhan, and R. Sütçü, “Serum neopterin and TNF-α levels in psoriasis and their correlation with disease severity,” Turkderm Deri Hastaliklari ve Frengi Arsivi, vol. 46, no. 1, pp. 7–10, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Kamata, Y. Tada, A. Tatsuta et al., “Serum lipocalin-2 levels are increased in patients with psoriasis,” Clinical and Experimental Dermatology, vol. 37, no. 3, pp. 296–299, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. T. H. Flo, K. D. Smith, S. Sato et al., “Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron,” Nature, vol. 432, no. 7019, pp. 917–921, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. J. B. Cowland and N. Borregaard, “Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans,” Genomics, vol. 45, no. 1, pp. 17–23, 1997. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Chakraborty, S. Kaur, S. Guha, and S. K. Batra, “The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer,” Biochimica et Biophysica Acta, vol. 1826, no. 1, pp. 129–169, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Calero, A. Rostagno, B. Frangione, and J. Ghiso, “Clusterin and Alzheimer's disease,” Sub-Cellular Biochemistry, vol. 38, pp. 273–298, 2005. View at Google Scholar · View at Scopus
  7. T. Nuutinen, T. Suuronen, A. Kauppinen, and A. Salminen, “Valproic acid stimulates clusterin expression in human astrocytes: Implications for Alzheimer's disease,” Neuroscience Letters, vol. 475, no. 2, pp. 64–68, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Falgarone and G. Chiocchia, “Chapter 8: clusterin: a multifacet protein at the crossroad of inflammation and autoimmunity,” Advances in Cancer Research, vol. 104, pp. 139–170, 2009. View at Google Scholar · View at Scopus
  9. J. Rothe, G. Gehr, H. Loetscher, and W. Lesslauer, “Tumor necrosis factor receptors-structure and function,” Immunologic Research, vol. 11, no. 2, pp. 81–90, 1992. View at Google Scholar · View at Scopus
  10. R. D. Kinloch, C. M. Lee, N. van Rooijen, and E. T. Morgan, “Selective role for tumor necrosis factor-α, but not interleukin-1 or Kupffer cells, in down-regulation of CYP3A11 and CYP3A25 in livers of mice infected with a noninvasive intestinal pathogen,” Biochemical Pharmacology, vol. 82, no. 3, pp. 312–321, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Kumari, M. C. Bonnet, M. H. Ulvmar et al., “Tumor necrosis factor receptor signaling in keratinocytes triggers interleukin-24-dependent psoriasis like skin inflammation in mice,” Immunity, vol. 39, pp. 899–911, 2013. View at Google Scholar
  12. A. Castells-Rodellas, J. V. Castell, A. Ramirez-Bosca, J. F. Nicolas, F. Valcuende-Cavero, and J. Thivolet, “Interleukin-6 in normal skin and psoriasis,” Acta Dermato-Venereologica, vol. 72, no. 3, pp. 165–168, 1992. View at Google Scholar · View at Scopus
  13. J. van Snick, “Interleukin-6: An overview,” Annual Review of Immunology, vol. 8, pp. 253–278, 1990. View at Google Scholar · View at Scopus
  14. P. B. Sehgal, “Interleukin-6: molecular pathophysiology,” Journal of Investigative Dermatology, vol. 94, pp. 2S–6S, 1990. View at Google Scholar · View at Scopus
  15. E. Fattori, M. Cappelletti, P. Costa et al., “Defective inflammatory response in interleukin 6-deficient mice,” Journal of Experimental Medicine, vol. 180, no. 4, pp. 1243–1250, 1994. View at Google Scholar · View at Scopus
  16. A. J. Martí-Carvajal, I. Solà, D. Lathyris, and G. Salanti, “Homocysteine lowering interventions for preventing cardiovascular events,” Cochrane Database of Systematic Reviews, no. 4, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Selhub, “Homocysteine metabolism,” Annual Review of Nutrition, vol. 19, pp. 217–246, 1999. View at Publisher · View at Google Scholar · View at Scopus
  18. F. Brian Boudi, “Noncoronary atherosclerosis overview of atherosclerosis,” Medscape, 2013. View at Google Scholar
  19. V. Brazzelli, V. Grasso, L. Fornara et al., “Homocysteine, vitamin B12 and folic acid levels in psoriatic patients and correlation with disease severity,” International Journal of Immunopathology and Pharmacology, vol. 23, no. 3, pp. 911–916, 2010. View at Google Scholar · View at Scopus
  20. F. H. McCrudden, Uric Acid, BiblioBazaar, 2008.
  21. J. Romani, A. Caixas, V. Ceperuelo-Mallafre et al., “Circulating levels of lipocalin-2 and retinol-binding protein-4 are increased in psoriatic patients and correlated with baseline PASI,” Archives of Dermatological Research, vol. 305, pp. 105–112, 2013. View at Google Scholar
  22. H. El-Hadidi, N. Samir, O. G. Shaker, and S. Otb, “Estimation of tissue and serum lipocalin-2 in psoriasis vulgaris and its relation to metabolic syndrome,” Archives of Dermatological Research, vol. 306, no. 3, pp. 239–45, 2014. View at Google Scholar
  23. E. Guttman-Yassky, M. A. Lowes, J. Fuentes-Duculan et al., “Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis,” Journal of Immunology, vol. 181, no. 10, pp. 7420–7427, 2008. View at Google Scholar · View at Scopus
  24. F. Shen, Z. Hu, J. Goswami, and S. L. Gaffen, “Identification of common transcriptional regulatory elements in interleukin-17 target genes,” Journal of Biological Chemistry, vol. 281, no. 34, pp. 24138–24148, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. J. H. Lee, K. C. Kye, E. Y. Seo et al., “Expression of neutrophil gelatinase-associated lipocalin in calcium-induced keratinocyte differentiation,” Journal of Korean Medical Science, vol. 23, no. 2, pp. 302–306, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. S. J. Seo, J. Y. Ahn, C. K. Hong et al., “Expression of neutrophil gelatinase-associated lipocalin in skin epidermis,” Journal of Investigative Dermatology, vol. 126, no. 2, pp. 510–512, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Mallbris, K. P. O'Brien, A. Hulthén et al., “Neutrophil gelatinase-associated lipocalin is a marker for dysregulated keratinocyte differentiation in human skin,” Experimental Dermatology, vol. 11, no. 6, pp. 584–591, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. D. Stejskal, M. Karpíšek, V. Humenanska et al., “Lipocalin-2: development, analytical characterization, and clinical testing of a new ELISA,” Hormone and Metabolic Research, vol. 40, no. 6, pp. 381–385, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. G. Wu, H. Li, M. Zhou et al., “Mechanism and clinical evidence of lipocalin-2 and adipocyte fatty acid-binding protein linking obesity and atherosclerosis,” Diabetes Metabolism Research and Reviews, 2013. View at Publisher · View at Google Scholar
  30. Y. Xiao, A. Xu, X. Hui et al., “Circulating lipocalin-2 and retinol-binding protein 4 are associated with intima-media thickness and subclinical atherosclerosis in patients with type 2 diabetes,” PLoS ONE, vol. 8, Article ID e66607, 2013. View at Google Scholar
  31. S. Garcia-Rodriguez, S. Arias-Santiago, R. Perandres-Lopez et al., “Decreased plasma levels of clusterin in patients with psoriasis,” Actas Dermosifiliogr, vol. 104, pp. 497–503, 2013. View at Google Scholar
  32. L. McLaughlin, G. Zhu, M. Mistry et al., “Apolipoprotein J/clusterin limits the severity of murine autoimmune myocarditis,” Journal of Clinical Investigation, vol. 106, no. 9, pp. 1105–1113, 2000. View at Google Scholar · View at Scopus
  33. V. Devauchelle, A. Essabbani, G. de Pinieux et al., “Characterization and functional consequences of underexpression of clusterin in rheumatoid arthritis,” Journal of Immunology, vol. 177, no. 9, pp. 6471–6479, 2006. View at Google Scholar · View at Scopus
  34. B. Blumenstein, F. Saad, S. Hotte et al., “Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen,” Cancer Medicine, vol. 2, pp. 468–477, 2013. View at Google Scholar
  35. E. Fandridis, G. Apergis, D. S. Korres et al., “Increased expression levels of apolipoprotein J/clusterin during primary osteoarthritis,” In Vivo, vol. 25, no. 5, pp. 745–749, 2011. View at Google Scholar · View at Scopus
  36. L. Wang, P. Erling, A. A. Bengtsson, L. Truedsson, G. Sturfelt, and D. Erlinge, “Transcriptional down-regulation of the platelet ADP receptor P2Y12 and clusterin in patients with systemic lupus erythematosus,” Journal of Thrombosis and Haemostasis, vol. 2, no. 8, pp. 1436–1442, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Tobisawa, M. Honna, A. Ishida-Yamamoto, Y. Saijo, and H. lizuka, “Prognostic factors in 105 Japanese cases of mycosis fungoides and Sezary syndrome: clusterin expression as a novel prognostic factor,” Journal of Dermatological Science, vol. 71, pp. 160–166, 2013. View at Google Scholar
  38. K. Yanaba, Y. Asano, Y. Tada, M. Sugaya, T. Kadono, and S. Sato, “A possible contribution of elevated serum clusterin levels to the inhibition of digital ulcers and pulmonary arterial hypertension in systemic sclerosis,” Archives of Dermatological Research, vol. 304, pp. 459–463, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Bettuzzi, “Chapter 1: introduction,” Advances in cancer research, vol. 104, pp. 1–8, 2009. View at Google Scholar · View at Scopus
  40. A. B. Serwin, M. Sokolowska, and B. Chodynicka, “Soluble tumor necrosis factor α receptor type 1 in psoriasis patients treated with narrowband ultraviolet B,” Photodermatology Photoimmunology and Photomedicine, vol. 21, no. 4, pp. 210–211, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. A. M. Brotas, J. M. Cunha, E. H. Lago, C. C. Machado, and S. C. Carneiro, “Tumor necrosis factoralpha and the cytokine network in psoriasis.,” Anais Brasileiros de Dermatologia, vol. 87, pp. 673–681, 2012. View at Google Scholar
  42. S. Coimbra, H. Oliveira, F. Reis et al., “Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumour necrosis factor-α levels in patients with psoriasis before, during and after psoralen-ultraviolet A and narrowband ultraviolet B therapy,” British Journal of Dermatology, vol. 163, no. 6, pp. 1282–1290, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. G.-M. Alenius, C. Eriksson, and S. R. Dahlqvist, “Interleukin-6 and soluble interleukin-2 receptor alpha—Markers of inflammation in patients with psoriatic arthritis?” Clinical and Experimental Rheumatology, vol. 27, no. 1, pp. 120–123, 2009. View at Google Scholar · View at Scopus
  44. V. H. Koliadenko and P. V. Chernyshov, “Interleukin-6 as a marker of the activity of a pathological process in patients with psoriasis,” Likars'ka Sprava, no. 5-6, pp. 80–82, 2005. View at Google Scholar · View at Scopus
  45. O. Arican, M. Aral, S. Sasmaz, and P. Ciragil, “Serum levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity,” Mediators of Inflammation, vol. 2005, no. 5, pp. 273–279, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. S. Kaur, K. Zilmer, C. Kairane, M. Kals, and M. Zilmer, “Clear differences in adiponectin level and glutathione redox status revealed in obese and normal-weight patients with psoriasis,” British Journal of Dermatology, vol. 159, no. 6, pp. 1364–1367, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. A. M. Tobin, R. Hughes, E. B. Hand, T. Leong, I. M. Graham, and B. Kirby, “Homocysteine status and cardiovascular risk factors in patients with psoriasis: a case-control study,” Clinical and Experimental Dermatology, vol. 36, no. 1, pp. 19–23, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Malerba, P. Gisondi, A. Radaeli, R. Sala, P. G. Calzavara Pinton, and G. Girolomoni, “Plasma homocysteine and folate levels in patients with chronic plaque psoriasis,” British Journal of Dermatology, vol. 155, no. 6, pp. 1165–1169, 2006. View at Publisher · View at Google Scholar · View at Scopus
  49. B. Vanizor Kural, A. Örem, G. Çimşit, H. A. Uydu, Y. E. Yandi, and A. Alver, “Plasma homocysteine and its relationships with atherothrombotic markers in psoriatic patients,” Clinica Chimica Acta, vol. 332, no. 1-2, pp. 23–30, 2003. View at Publisher · View at Google Scholar · View at Scopus
  50. H. Refsum, S. Helland, and P. M. Ueland, “Fasting plasma homocysteine as a sensitive parameter of antifolate effect: a study of psoriasis patients receiving low-dose methotrexate treatment,” Clinical Pharmacology and Therapeutics, vol. 46, no. 5, pp. 510–520, 1989. View at Google Scholar · View at Scopus
  51. O. Karabudak, R. Eralp Ulusoy, A. Akyol Erikci, E. Solmazgul, B. Dogan, and Y. Harmanyeri, “Inflammation and hypercoagulable state in adult psoriatic men,” Acta Dermato-Venereologica, vol. 88, no. 4, pp. 337–340, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. A. G. Richetta, C. Mattozzi, L. Macaluso et al., “Homocysteine plasmatic status in patients with psoriasis,” European Journal of Dermatology, vol. 21, no. 4, pp. 621–623, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. S. K. Cakmak, U. Gul, C. Kilic, M. Gonul, S. Soylu, and A. Kilic, “Homocysteine, vitamin B12 and folic acid levels in psoriasis patients,” Journal of the European Academy of Dermatology and Venereology, vol. 23, pp. 300–303, 2009. View at Google Scholar
  54. E. Christophers and U. Mrowietz, “Psoriasis,” in Dermatology in General Medicine, T. B. Fitzpatrick, I. M. Freedberg, A. Z. Eisen et al., Eds., pp. 407–427, McGraw-Hill, New York, NY, USA, 6th edition, 2003. View at Google Scholar
  55. P. Gisondi, G. Targher, A. Cagalli, and G. Girolomoni, “Hyperuricemia in patients with chronic plaque psoriasis,” Journal of the American Academy of Dermatology, vol. 70, pp. 127–130, 2014. View at Google Scholar
  56. G. Grzybowski, I. Fafara, R. Zaba, and B. Wierusz-Wysocka, “Evaluation of glucose, insulin, C-peptide uric acid serum levels in patients with psoriasis,” Polski Merkuriusz Lekarski, vol. 11, no. 66, pp. 495–498, 2001. View at Google Scholar · View at Scopus
  57. E. Severin, B. Nave, M. Ständer, R. Ott, and H. Traupe, “Total antioxidative capacity is normal in sera from psoriasis patients despite elevated bilirubin, tocopherol and urate levels,” Dermatology, vol. 198, no. 4, pp. 336–339, 1999. View at Publisher · View at Google Scholar · View at Scopus
  58. H. H. Kwon, I. H. Kwon, J. W. Choi, and J. I. Youn, “Cross-sectional study on the correlation of serum uric acid with disease severity in Korean patients with psoriasis,” Clinical and Experimental Dermatology, vol. 36, no. 5, pp. 473–478, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. I. Isha, V. K. Jain, and H. Lal, “C-reactive protein and uric acid levels in patients with psoriasis,” Indian Journal of Clinical Biochemistry, vol. 26, no. 3, pp. 309–311, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. T. J. Angelopoulos, J. Lowndes, L. Zukley et al., “The effect of high-fructose corn syrup consumption on triglycerides and uric acid,” Journal of Nutrition, vol. 139, pp. 1242S–1245S, 2009. View at Publisher · View at Google Scholar · View at Scopus